A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

Summary

The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in adolescents (≥ 12 years up to \< 18 years of age). Participants who will complete the total 52-week treatment period will have the opportunity to continue in a Long-Term Extension (LTE) Period of up to 4 years (5 years after study enrollment).

Timeline

Start

2022-12-16

Primary completion

2029-06-16

Completion

2033-07-10

Drugs

Indications